Table of Content

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Proliferative Diabetic Retinopathy Market

4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, 2017–2031

5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry

6. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Class, 2017–2031
        6.3.1. Anti-VEGF Agents
        6.3.2. Corticosteroids
    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Mode of Administration
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Mode of Administration, 2017–2031
        7.3.1. Injectable
        7.3.2. Oral
        7.3.3. Others
    7.4. Market Attractiveness Analysis, by Mode of Administration

8. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017–2031
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2017–2031
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region

10. North America Proliferative Diabetic Retinopathy Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Drug Class, 2017–2031
        10.3.1. Anti-VEGF Agents
        10.3.2. Corticosteroids
    10.4. Market Value Forecast, by Mode of Administration, 2017–2031
        10.4.1. Injectable
        10.4.2. Oral
        10.4.3. Others
    10.5. Market Value Forecast, by Distribution Channel, 2017–2031
        10.5.1. Hospital Pharmacies
        10.5.2. Retail Pharmacies
        10.5.3. Online Pharmacies
    10.6. Market Value Forecast, by Country, 2017–2031
        10.6.1. U.S.
        10.6.2. Canada
    10.7. Market Attractiveness Analysis
        10.7.1. By Drug Class
        10.7.2. By Mode of Administration
        10.7.3. By Distribution Channel
        10.7.4. By Country

11. Europe Proliferative Diabetic Retinopathy Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Drug Class, 2017–2031
        11.3.1. Anti-VEGF Agents
        11.3.2. Corticosteroids
    11.4. Market Value Forecast, by Mode of Administration, 2017–2031
        11.4.1. Injectable
        11.4.2. Oral
        11.4.3. Others
    11.5. Market Value Forecast, by Distribution Channel, 2017–2031
        11.5.1. Hospital Pharmacies
        11.5.2. Retail Pharmacies
        11.5.3. Online Pharmacies
    11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.6.1. Germany
        11.6.2. U.K.
        11.6.3. France
        11.6.4. Italy
        11.6.5. Spain
        11.6.6. Rest of Europe
    11.7. Market Attractiveness Analysis
        11.7.1. By Drug Class
        11.7.2. By Mode of Administration
        11.7.3. By Distribution Channel
        11.7.4. By Country/Sub-region

12. Asia Pacific Proliferative Diabetic Retinopathy Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Drug Class, 2017–2031
        12.3.1. Anti-VEGF Agents
        12.3.2. Corticosteroids
    12.4. Market Value Forecast, by Mode of Administration, 2017–2031
        12.4.1. Injectable
        12.4.2. Oral
        12.4.3. Others
    12.5. Market Value Forecast, by Distribution Channel, 2017–2031
        12.5.1. Hospital Pharmacies
        12.5.2. Retail Pharmacies
        12.5.3. Online Pharmacies
    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.6.1. China
        12.6.2. Japan
        12.6.3. India
        12.6.4. Australia & New Zealand
        12.6.5. Rest of Asia Pacific
    12.7. Market Attractiveness Analysis
        12.7.1. By Drug Class
        12.7.2. By Mode of Administration
        12.7.3. By Distribution Channel
        12.7.4. By Country/Sub-region
13. Latin America Proliferative Diabetic Retinopathy Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Drug Class, 2017–2031
        13.3.1. Anti-VEGF Agents
        13.3.2. Corticosteroids
    13.4. Market Value Forecast, by Mode of Administration, 2017–2031
        13.4.1. Injectable
        13.4.2. Oral
        13.4.3. Others
    13.5. Market Value Forecast, by Distribution Channel, 2017–2031
        13.5.1. Hospital Pharmacies
        13.5.2. Retail Pharmacies
        13.5.3. Online Pharmacies
    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.6.1. Brazil
        13.6.2. Mexico
        13.6.3. Rest of Latin America
    13.7. Market Attractiveness Analysis
        13.7.1. By Drug Class
        13.7.2. By Mode of Administration
        13.7.3. By Distribution Channel
        13.7.4. By Country/Sub-region
14. Middle East & Africa Proliferative Diabetic Retinopathy Market Analysis and Forecast
    14.1. Introduction
    14.2. Key Findings
    14.3. Market Value Forecast, by Drug Class, 2017–2031
        14.3.1. Anti-VEGF Agents
        14.3.2. Corticosteroids
    14.4. Market Value Forecast, by Mode of Administration, 2017–2031
        14.4.1. Injectable
        14.4.2. Oral
        14.4.3. Others
    14.5. Market Value Forecast, by Distribution Channel, 2017–2031
        14.5.1. Hospital Pharmacies
        14.5.2. Retail Pharmacies
        14.5.3. Online Pharmacies
    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.6.1. GCC Countries
        14.6.2. South Africa
        14.6.3. Rest of Middle East & Africa
    14.7. Market Attractiveness Analysis
        14.7.1. By Drug Class
        14.7.2. By Mode of Administration
        14.7.3. By Distribution Channel
        14.7.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2022)
    15.3. Company Profiles
        15.3.1. Genentech, Inc.
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Financial Overview
            15.3.1.5. Strategic Overview
        15.3.2. Novartis AG
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Financial Overview
            15.3.2.5. Strategic Overview
        15.3.3. Regeneron Pharmaceuticals, Inc.
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Financial Overview
            15.3.3.5. Strategic Overview
        15.3.4. Pfizer Inc.
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Financial Overview
            15.3.4.5. Strategic Overview
        15.3.5. Merck KGaA
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Financial Overview
            15.3.5.5. Strategic Overview
        15.3.6. Cipla Inc.
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Financial Overview
            15.3.6.5. Strategic Overview
        15.3.7. AbbVie Inc.
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Financial Overview
            15.3.7.5. Strategic Overview
        15.3.8. Bausch Health Companies Inc.
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Financial Overview
            15.3.8.5. Strategic Overview
        15.3.9. Santen Pharmaceutical Co., Ltd.
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Financial Overview
            15.3.9.5. Strategic Overview
        15.3.10. Alimera Sciences
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Financial Overview
            15.3.10.5. Strategic Overview
        15.3.11. Intas Pharmaceuticals Ltd.
            15.3.11.1. Company Overview
            15.3.11.2. Product Portfolio
            15.3.11.3. SWOT Analysis
            15.3.11.4. Financial Overview
            15.3.11.5. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031

Figure 02: Global Proliferative Diabetic Retinopathy Market Revenue (US$ Mn), by Drug Class, 2022

Figure 03: Global Proliferative Diabetic Retinopathy Market Value Share, by Drug Class, 2022

Figure 04: Global Proliferative Diabetic Retinopathy Market Revenue (US$ Mn), by Mode of Administration, 2022

Figure 05: Global Proliferative Diabetic Retinopathy Market Value Share, by Mode of Administration, 2022

Figure 06: Global Proliferative Diabetic Retinopathy Market Revenue (US$ Mn), by Distribution Channel, 2022

Figure 07: Global Proliferative Diabetic Retinopathy Market Value Share, by Distribution Channel, 2022

Figure 08: Global Proliferative Diabetic Retinopathy Market Value Share, by Region, 2022

Figure 09: Global Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast, 2017–2031

Figure 10: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 11: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023-2031

Figure 12: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 13: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023-2031

Figure 14: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 15: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2022-2031

Figure 16: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Region, 2022 and 2031

Figure 17: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Region, 2022-2031

Figure 18: North America Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country, 2023–2031

Figure 20: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country, 2022 and 2031

Figure 21: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 22: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 23: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 24: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 25: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031

Figure 26: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 27: Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 30: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 31: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 32: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 33: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 34: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031

Figure 35: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 36: Asia Pacific Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 39: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 40: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 41: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 42: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 43: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031

Figure 44: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 45: Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 47: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 48: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 49: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 50: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 51: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 52: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031

Figure 53: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 54: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 56: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 57: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 58: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031

Figure 59: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 60: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031

Figure 61: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031

Figure 62: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031

List of Tables

List of Tables

Table 01: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 03: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 07: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 08: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 11: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 12: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 16: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 19: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 20: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 23: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031

Table 24: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031